Basal cell carcinoma (BCC) is the dermatological neoplasm more prevalent worldwide, in recent years there has been an increase in the number of cases becoming a health problem. Despite its high incidence, there is little information about genetic factors that lead to the carcinogenesis of this neoplasms. In the last years, macrophage migration inhibitory factor (MIF) has received particular attention, its expression has been linked to the development of different types of cancer. Therefore, the aim of this study was to investigate the genetic association of −794 CATT5–8 and −173 G>C MIF polymorphisms with BCC.
A total of 150 BCC patients and 150 individuals with similar age than cases as a control group were recruited. Total genomic DNA was extracted from peripheral blood leukocytes by the salting out method. The −794 CATT5–8 MIF polymorphism was analyzed by conventional PCR and polyacrylamide gel electrophoresis, the −173 G>C MIF polymorphism was genotyped by PCR-RFLP as was done in previous studies by our research group.
It was found that BCC incidence is higher in women than men additionally the localization of this neoplasia are more prevalent in head and neck. Also, it was found that the 5/5 genotype of the −794 CATT5–8 MIF polymorphisms of confers a risk to BCC development (OR=4.55, p=0.04). Respect to the −173 G>C MIF polymorphism we did not find a statistical difference.
In conclusion, our findings suggest that the 5/5 genotyope of −794 CATT5–8 MIF polymorphism is associated with the development of BCC in patients from western Mexico. Further studies are needed due to the relation of the functions of MIF and de development of cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.